Topical ENS-002 for Atopic Dermatitis in Adults (EnSync)
Phase 1 First in Human Dose Escalation and Safety Study of Topical ENS-002 for Atopic Dermatitis in Adults
Sponsor: Concerto Biosciences
Terminated
Planned safety, efficacy and proof of mechanism obtained
Listed as NCT06469385, this PHASE1 trial focuses on Atopic Dermatitis and Atopic Dermatitis Eczema and remains terminated or withdrawn. Sponsored by Concerto Biosciences, it has been updated 8 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE1
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Concerto Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .